Cargando…

Selected protein expression in a new prognostic model for patients with non-muscle-invasive bladder cancer

INTRODUCTION: After transurethral resection of a bladder tumor, patients frequently have a recurrence of the disease, thereby requiring adjuvant therapy. PURPOSE: The study aimed to determine the prognostic value of expression levels of p53, Ki-67, and survivin, and to develop a new prognostic model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semeniuk-Wojtaś, Aleksandra, Lubas, Arkadiusz, Cierniak, Szczepan, Brzóskowska, Urszula, Syryło, Tomasz, Zieliński, Henryk, Stec, Rafał
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324417/ https://www.ncbi.nlm.nih.gov/pubmed/32239282 http://dx.doi.org/10.1007/s00432-020-03202-0

Ejemplares similares

Intensity of Nuclear Staining for Ki-67, p53 and Survivin as a New Prognostic Factor in Non-muscle Invasive Bladder Cancer
por: Stec, Rafał, et al.
Publicado: (2019)

Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2023)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Oncometabolites—A Link between Cancer Cells and Tumor Microenvironment
por: Baryła, Maksymilian, et al.
Publicado: (2022)

Evaluation of Polysaccharide–Peptide Conjugates Containing the RGD Motif for Potential Use in Muscle Tissue Regeneration
por: Kolasa, Marcin, et al.
Publicado: (2022)

A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer
por: Xu, Zhijie, et al.
Publicado: (2021)

Preliminary trial of 24 vs 72 hour perioperative meropenem in patients with ESBL-producing Enterobacterales bacteriuria scheduled for urological procedures
por: Radko, Marcin, et al.
Publicado: (2022)

Muscle-invasive angiosarcoma of the urinary bladder: Case report
por: Madiraju, Srigita, et al.
Publicado: (2023)

Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
por: Cheng, Xiangming, et al.
Publicado: (2018)

Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration
por: Zhang, Xiaolong, et al.
Publicado: (2021)

Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
por: Zhou, Xianghong, et al.
Publicado: (2020)

Muscle-invasive bladder cancer following radiotherapy for prostate adenocarcinoma
por: Barnett, Jack, et al.
Publicado: (2020)

Non-muscle invasive bladder cancer biomarkers beyond morphology
por: De Carlo, Camilla, et al.
Publicado: (2022)

Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
por: Katayama, Satoshi, et al.
Publicado: (2022)

Testosterone Replacement Therapy in Chronic Kidney Disease Patients
por: Skiba, Ryszard, et al.
Publicado: (2022)

Minimally invasive transnasal approach for primary ectopic meningioma of the paranasal sinuses
por: Szczygielski, Kornel, et al.
Publicado: (2015)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
por: Li, Shuaishuai, et al.
Publicado: (2022)

Selected Immunohistochemical Assessment and Clinical Examinations in the Diagnosis of Palatine Tonsil Diseases
por: Bant, Przemysław, et al.
Publicado: (2023)

Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis
por: Ślusarczyk, Aleksander, et al.
Publicado: (2023)

Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response
por: Annels, Nicola E., et al.
Publicado: (2020)

Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis
por: Deng, Sheng, et al.
Publicado: (2022)

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective
por: Yang, Yongjun, et al.
Publicado: (2023)

Case Report: Echinocandin-Resistance Candida glabrata FKS Mutants From Patient Following Radical Cystoprostatectomy Due to Muscle-Invasive Bladder Cancer
por: Szymankiewicz, Maria, et al.
Publicado: (2021)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Pyeloduodenal fistula complicating neoadjuvant chemotherapy in a patient diagnosed with muscle invasive bladder cancer
por: Alanee, Shaheen
Publicado: (2019)

Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer
por: Zhang, Jinghua, et al.
Publicado: (2021)

Bacillus Calmette–Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer
por: Su, Fei, et al.
Publicado: (2022)

The role of radiomics with machine learning in the prediction of muscle-invasive bladder cancer: A mini review
por: Huang, Xiaodan, et al.
Publicado: (2022)

Serum metabolites as early detection markers of non-muscle invasive bladder cancer in Chinese patients
por: Zhao, Yi, et al.
Publicado: (2023)

An MRI-based radiomics nomogram in predicting histologic grade of non-muscle-invasive bladder cancer
por: Li, Longchao, et al.
Publicado: (2023)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Knowledge of and Compliance With Guidelines in the Management of Non-Muscle-Invasive Bladder Cancer: A Survey of Chinese Urologists
por: Wang, Dan-Qi, et al.
Publicado: (2021)

A review of the biology and therapeutic implications of cancer-associated fibroblasts (CAFs) in muscle-invasive bladder cancer
por: Burley, Amy, et al.
Publicado: (2022)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

CT-based deep learning radiomics signature for the preoperative prediction of the muscle-invasive status of bladder cancer
por: Chen, Weitian, et al.
Publicado: (2022)

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
por: Grabe-Heyne, Kristin, et al.
Publicado: (2023)

Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans
por: Knapp, Deborah W., et al.
Publicado: (2020)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_htvk9m6c2af3m7j7tfktrq4mqm